A Massive Catalyst - Wall Street gets psychedelic MindMed tomorrow is set to become the second psychedelic drug developer to go public in the U.S., with a third right around the corner (ATAI Life Sciences).
This will surely raise the profile of all pysch companies to American investors (not many public options to choose from). During the early-Cannabis days, exposure to American investor-base was a massive catalyst for Canadian companies as American investors were seeking to capitalize on nascent-stage industry.
The pandemic has increased public awareness of the scale of mental health ailments, and the relative paucity of available treatments and treatment infrastructure. The time for the industry to explode is now.
Numi is also about to cross private-placement price of $1.25, which will likely be another key catalyst for the stock. I wouldn't be surprised to see this stock surpassing $2.23 all time high within a matter of weeks / months.
GLTA!!!!!!!!!!